FindTrial
Sign In

To study the relation of tumor buds in breast cancer.

To study the utility of Tumor budding as a histopathological marker in comparison to histopathological prognostic markers, TNM staging in Breast Cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/053335
Enrollment
65
Registered
2023-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: NIL: NIL

Sponsors

Jawaharalal Nehru Medical College
Lead Sponsor
Jawaharlal Nehru Medical College
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria- 1. Histopathologically confirmed cases of Breast carcinoma. 2. Specimens of all modified radical mastectomy specimens. 3. Females diagnosed with breast carcinoma. 4. Newly diagnosed cases of breast cancer.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with other lesions other than breast carcinoma- myoepithelial tumors, fibroepithelial tumors, mesenchymal tumors, benign tumors and mastectomy specimens. 2. Patient with history of lobectomy and biopsy specimen including both Tru cut biopsies and wedge biopsies. 3. Male patient diagnosed with breast cancer. 4. Patient with history of Neo Adjuvant therapy.

Design outcomes

Primary

MeasureTime frame
Increased tumor budding shows poor prognosis in breast cancer patients.Timepoint: 2 years—

Secondary

MeasureTime frame
To compare tumor budding with other histopathological prognostic markers and TNM staging in breast cancer.Timepoint: 2 years—

Countries

India

Contacts

Public ContactSoumya Agrawal

Jawaharlal Nehru Medical College

sunitavagha@gmail.com09860244638

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026